Levosimendan Kabi (Levosimendan)

Levosimendan is a calcium sensitizer used in the management of heart failure.

• Acute decompensated heart failure: improves cardiac output and relieves symptoms of fluid overload.
• Severe chronic heart failure: enhances myocardial contractility and may improve functional status.
• Low‑output heart failure: increases stroke volume and supports systemic circulation when conventional therapy is insufficient.

• Levosimendan binds to cardiac troponin C, stabilizing its calcium‑bound state and thereby increasing the sensitivity of the contractile apparatus to calcium without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, producing vasodilation and reducing after‑load, which together improve overall cardiac performance.

Levosimendan may cause a range of adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient drop in blood pressure.
• Nausea: occasional gastrointestinal upset.
• Dizziness: related to blood pressure changes.
• Flushing: warm sensation and skin reddening.
• Arrhythmia: occasional premature beats.

Serious or Rare Side Effects

• Severe hypotension: may require intervention.
• Ventricular arrhythmias: potentially life‑threatening.
• Myocardial ischemia: chest pain or ECG changes.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Tachycardia: rapid heart rate.
• Liver enzyme elevation: abnormal hepatic function tests.

Levosimendan should be used with careful clinical monitoring.

• Blood pressure monitoring: observe for hypotension during infusion.
• Cardiac rhythm monitoring: watch for arrhythmias, especially in patients with pre‑existing conduction disorders.
• Electrolyte assessment: correct imbalances before administration.
• Caution in renal or hepatic impairment: dose adjustment may be required.
• Avoid concurrent strong vasodilators: risk of profound hypotension.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levosimendan may interact with several cardiovascular agents.

Major Interactions (Avoid)

• Concomitant strong vasodilators (e.g., nitroglycerin): can cause severe hypotension.
• Other inotropic agents (e.g., dopamine): may increase risk of arrhythmias.
• Phosphodiesterase inhibitors (e.g., milrinone): additive vasodilatory effect.

Moderate Interactions (Monitor Closely)

• Beta‑blockers: may blunt desired inotropic response.
• ACE inhibitors or ARBs: monitor blood pressure closely.
• Diuretics: assess volume status and electrolytes.
• Antiarrhythmic drugs: observe for rhythm disturbances.
• Anticoagulants: watch for bleeding if hypotension occurs.